IRCT20151227025726N20
Completed
Phase 2
Evaluating the efficacy and safety of intravenous immunoglobulin (IVIG) in COVID-19 patients
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Enrollment
- 80
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients between 18 and 65 years old.
- •Laboratory confirmed COVID\-19 (Corona Virus Disease\-19\) with RT\-PCR (Real\-Time Polymerase Chain Reaction).
- •Severely ill patients.
- •Bilateral pulmonary infiltration.
- •SPO2 (Peripheral Capillary Oxygen Saturation) less than 90% (at rest with nasal cannula 3\-4 L/min and FIO2 less than 30\-40 L/min).
- •Signed consent form.
Exclusion Criteria
- •Allergy reaction while injecting IVIG with severe extravasation and anaphylactic shock.
- •Mildly ill patient.
- •Pregnancy or breast feeding.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients with Iron Deficiency AnemiaEUCTR2019-003821-70-PLAmerican Regent, Inc.10
Active, not recruiting
Not Applicable
intravenous immunoglobulin for the treatment of infections in patients with post solid organ transplantation hypogammaglobulinemiainfections in patients with post solid organ transplantation IgG hypogammaglobulinemiaMedDRA version: 15.0Level: LLTClassification code 10054427Term: HypogammaglobulinemiaSystem Organ Class: 10021428 - Immune system disordersTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2012-001327-12-ESFundacion para la Investigación Biomédica del Hospital Gregorio Marañón
Active, not recruiting
Phase 1
Study with hzVSF-v13 in patients with COVID-19 pneumonia: a phase II, proof of concept, multicentre, randomized, parallel-group, double-blind, placebo-controlled studyModerate-to-severe COVID-19 pneumoniaMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2020-003614-13-ITImmuneMed Inc.105
Not yet recruiting
Phase 4
Efficacy and Saftey of Intravenous Versus Oral Iron Therapy in Postpartum Anemia - A Randomised Controlled TrialCTRI/2020/02/023125Department of Obstetrics And Gynecology
Not yet recruiting
Phase 4
Comparing Tramadol vs Paracetamol for Pain Relief in Acute Pancreatitis: A Randomized Controlled TrialCTRI/2024/06/068751DR ABHIJEET SHRIDHAR